M&As this week: Varian, Nordson Corporation, Boston Scientific

19 October 2018 (Last Updated October 19th, 2018 16:16)

Varian has acquired Noona Healthcare in a transaction, whose financial details are not disclosed.

Varian has acquired Noona Healthcare in a transaction, whose financial details are not disclosed.

Varian plans to integrate its 360 Oncology SaaS platform with Noona’s cloud-based mobile service, which enables communication between cancer patient-reported outcomes (PRO) and clinics capture.

The integration will offer a complete treatment, recovery and post-treatment platform by actively engaging patients with their cancer care team. The company also plans to further expand Noona’s portfolio, following the acquisition.

Based in the US, Varian is engaged in the development of cancer care solutions, while Noona, also based in the US, is a developer of cloud-based mobile services.

The acquisition is expected to expand Varian’s portfolio of cancer care solutions and is also part of the company’s long-term growth and value creation strategy.

Nordson Corporation has completed the acquisition of Clada Medical Devices.

Clada will be integrated into Nordson’s advanced technology systems segment, upon completion of the transaction.

The acquisition is in line with Nordson’s strategy to expand its presence in the minimally invasive medical device sector. It will enhance Nordson’s design and development capabilities and strengthen its position in the component manufacturing sector.

Based in the US, Nordson is involved in the development and manufacture of dispensing systems, while Clada Medical Devices is an Ireland-based company focused on the design and development of balloons and balloon catheters.

“The SpaceOAR® Hydrogel System helps to reduce the side effects of radiotherapy experienced by men undergoing treatment for prostate cancer.”

The financial details of the transaction have not been disclosed.

Boston Scientific has completed the acquisition of Augmenix for $500m in cash.

Augmenix will also receive up to $100m in sales-based milestones, as part of the transaction.

Augmenix is the developer of the SpaceOAR® Hydrogel System, a biodegradable hydrogel, which helps to reduce the side effects of radiotherapy experienced by men undergoing treatment for prostate cancer.

The gel is injected between the rectum and prostate to reduce radiation exposure and to reduce rectal radiation injury. The SpaceOAR Hydrogel System will add to Boston Scientific’s existing benign prostatic hyperplasia treatment portfolio, which includes the Rezūm® System, the GreenLight XPS Laser Therapy System, and holmium laser platforms. It will also strengthen the company’s leadership in prostate health.

Based in the US, Boston Scientific is a medical device manufacturer, while Augmenix, also based in the US, is a privately held company focused on the development and commercialisation of the SpaceOAR® Hydrogel System.